Search

Abstract Thyroid cancer keeps rapidly increasing worldwide and the most frequent type is papillary thyroid carcinoma (PTC). MicroRNAs (miRNAs) are proved dysregulated in many types of malignancies, including thyroid cancer. Although miR-let-7e has been implicated in several types of cancer regulation, relatively little is known about the function of miR-let-7e in PTC. In this study, we showed that the overexpression of miR-let-7e or knockdown of high mobility group box 1 (HMGB1) inhibited cell migration and invasion. MiR-let-7e downregulates HMGB1 expression by directly targeting the HMGB1 3′-UTR. Furthermore, HMGB1 reintroduction reversed the anti-proliferation, anti-migration, and anti-invasion roles of miR-let-7e. miR-let-7e might function as a tumor suppressor in papillary thyroid carcinoma through HMGB1. Therefore, our study demonstrates that miR-let-7e plays an important role in papillary thyroid carcinoma progression and might represent a new potential therapeutic target for treatment. [ABSTRACT FROM AUTHOR]

Abstract: Purpose: To investigate the protective effects of berberine on radiation-induced lung injury (RILI) in non-small cell lung cancer (NSCLC) patients treated with radiotherapy. Patients and methods: In this randomised, double-blind study, 90 patients with NSCLC were divided into two groups. The trial group received radiation therapy plus berberine, and the control group received radiation therapy plus a placebo for 6 weeks. Soluble intercellular adhesion molecular-1 (sICAM-1) and transforming growth factor-beta-1 (TGF-β1) were measured. RILI and pulmonary function were evaluated at 6 weeks and 6 months after treatment, respectively. Results: Of the 90 patients enroled, 43 in the control group and 42 in the trial group completed the study. The incidence of RILI was significantly lower in the trial group at 6 weeks and 6 months than that in the control group (45.2% versus 72.1% and 35.7% versus 65.1%, respectively, both P <0.05). sICAM-1 levels in the trial group were significantly lower at weeks 6 and 12 (373.64±89.33 versus 459.53±123.59 and 447.83±111.21 versus 513.91±150.46, both P <0.01), and plasma TGF-β1 levels were lower at week 3 and 6 (5.43±1.47 versus 6.22±1.78 and 5.93±2.39 versus 7.67±2.74, P <0.05 and 0.01, respectively) in comparison with the control group. Significant differences were observed in FEV1 (P =0.033) and DLCO (P =0.003) between patients receiving berberine and those receiving placebo. Independent-samples T-test showed reductions from baseline FVC at week 6 (P <0.05), and FEV1 and DLCO at month 6 (P <0.05 and 0.01, respectively) in the trial group were significantly smaller than that in the control group. Conclusion: Berberine significantly reduced the incidence of RILI, improved PF and decreased the levels of sICAM-1 and TGF-β1. The exact mechanisms remain to be further explored. [Copyright &y& Elsevier]

Accumulating evidence has suggested that long noncoding RNAs (lncRNAs) are involved in the progression of types of human cancers. It has been known that exosomes can mediate cell-cell crosstalk by transferring lncRNAs in tumor progression. This study aimed to investigate the role of exosomal lncRNA HEIH on cisplatin (DDP) resistance in tongue squamous cell carcinoma (TSCC). The expression of HEIH in human oral keratinocytes cell line (HOK), DDP-sensitive TSCC cell line (SCC4/S) and DDP-resistant TSCC cell line (SCC4/DDP) was measured. SCC4/S and SCC4/DDP cells were transfected with sh-HEIH to examine TSCC cell proliferation and apoptosis. The DDP-resistant exosomes were extracted and identified. The expression of miR‑3619-5p and TDGF in DDP-sensitive recipient cells was determined. The binding capacity between HEIH and miR‑3619-5p, along with miR‑3619-5p and TDGF was verified. HEIH expression was significantly upregulated in SCC4/DDP cells. Downregulation of HEIH inhibited DDP resistance and cell proliferation and promoted cell apoptosis. HEIH acted as a competing endogenous RNA (ceRNA) for miR‑3619-5p to upregulate HDGF expression. Exosomal HEIH promoted cell proliferation and drug resistance and inhibited cell apoptosis by sponging miR‑3169-5p and upregulating HDGF. Exosomal HEIH acted as a ceRNA for miR‑3619-5p to upregulate HDGF, thereby promoting DDP resistance in TSCC cells. [ABSTRACT FROM AUTHOR]

Abstract: Introduction: T helper 1 cell (Th1) polarization persists in the autoimmune response found in immune thrombocytopenia (ITP). Toll-like receptor 7 (TLR7) expression, which also plays an important role in autoimmune diseases, was verified to increase in ITP. However, the exact role of TLR7 in ITP is not well elucidated. Here, we explored the hypothesis that TLR7 participates in the pathophysiology of ITP by affecting Th1 polarization. Materials and methods: Twenty-two ITP patients and twenty-one controls were enrolled in this study. We examined the cytokine secretion of macrophages in ITP patients and controls using both TLR7 agonist (imiquimod) and antagonist (IRS 661). The influence of macrophage secretion from these groups and its effects on Th1/Th2 differentiation were subsequently studied. Effects of TLR7 on Th1/Th2 balance and platelet counts were also studied in vivo using a thrombocytopenic mouse model. Results: In in vitro assays, imiquimod enhanced interleukin (IL)-12 secretion in macrophages from ITP patients inducing Th1 differentiation. However, IRS 661 had the exact opposite effect and skewed Th differentiation towards the Th2 subset in ITP. Results from our in vivo studies indicated that injection of imiquimod in ITP mice resulted in elevated plasma levels of IFN-γ and decreased platelet counts. Nevertheless, injection of IRS 661 resulted in elevated plasma levels of IL-4 and platelet counts. Conclusion: These findings indicate that TLR7 promotes Th1 polarization and may contribute thus in the pathogenesis of ITP. [Copyright &y& Elsevier]

To explore the value of modified intraoperative real-time 125I seed implantation planning for lumbar lymph nodes metastases. We collected 26 lymph nodes metastases patients, who received 125I seed implantation from January 2015 to December 2021. 13 patients procedure were guided by modified intraoperative real-time treatment plan, and the rest were guided by conventional treatment plan. To compare the differences of the dosimetric parameters between pre-plan and post-plan of the 2 groups, and the percentage difference of the dosimetric parameters between the 2 groups. Then evaluate the curative effect and side effects after 6-month. There were no significant differences in dosimetric parameters between pre-plan and post-plan in modified intraoperative real-time treatment plan group, and showed significant differences in V 150 between pre-plan and post-plan in conventional treatment plan group(z =-3.045, P <0.001), and the rest dosimetric parameters of conventional treatment plan group showed no significant differences beforeand after operation(P >0.05). The percentage difference of V 150 between the 2 groups showed statistically significant(z =2.103 , P =0.004), and the rest dosimetric parameters showed no significant differences(P >0.05).6 months after the brachytherapy, the effective rate of Modified intraoperative real-time treatment plan group was 77%(10/13), and 46%(6/13) in Conventional treatment plan group, and no peritonitis and hemorrhage were observed. The application of modified real-time planning improved accuracy of dosimetric, reduced the high dose rate area, and provide guarantee for 125I seed implantation planning for lumbar lymph nodes metastases. [ABSTRACT FROM AUTHOR]

To investigate the relationship between dose parameters and tumor volume reduction ratio after 125I seed implantation for recurrent cervical squamous cell carcinoma, and to obtain the better parameters to predict the curative effect. 26 cervical squamous cell carcinoma patients with 30 lesions were studied retrospectively in our clinic. All patients underwent dose verification immediately after operation, and obtained postoperative D 90 (the minimum peripheral dose accepted by 90% target volume). The patients were followed up regularly. According to the CT images during the actual follow-up, the tumor volume reduction ratio at the end of t months (R t),the tumor volume reduction ratio 1 month after operation (R 1), the first month actual absorbed dose (D 1m), the first month efficacy corrected absorbed dose (D 1e), the first month sensitivity corrected absorbed dose (D 1s) and the t months actual absorbed dose (D t) were calculated. Curve fitting was performed for postoperative D90 and R1, and curve fitting was performed for postoperative D 90 , D 1m , D 1e , D 1s and R t to find the correlation between each parameter and tumor volume reduction ratio. The mean values of D 90 ,D 1m ,D 1e ,D 1s ,R t ,R 1 were (105.4±22.8) Gy,(30.9±7.4)Gy,(37.1±8.9)Gy,(37.8±11.6)Gy,(39.4±17)%,(20.4±12)%. Postoperative D 90 and R 1 , postoperative D 90 , D 1m , D 1e , D 1s andR t all have positive relationship. The equations are as follows y=6.856×10-7x3-2.66×10-4x2+0.031x-0.879(R2=0.139),y=1.573×10-6x3-4.47×10-4x2+0.045x-0.967(R2=0.027),y=7.11×10-5x3-0.07x2+0.193x-1.402(R2=0.043),y=3.546×10-5x3-0.003x2+0.108x-0.744(R2=0.126),y=1.022×10-5x3-0.001x2+0.048x-0.275(R2=0.243). PostoperativeD 90 , D 1m , D 1e and D 1s were positively correlated with postoperative tumor volume reduction ratio, which can be used to predict the efficacy of primary recurrent cervical squamous cell carcinoma patients with particle implantation. Compared with D 90 and D 1m , and D 1e , D 1s can be better predictors. [ABSTRACT FROM AUTHOR]

• Induction ICIs followed by RT might improve survival and locoregional control. • RT after ICIs brought survival benefits compared with historical evidence. • Consolidation ICIs after RT might be associated with improved survival. • 1These authors contributed equally to the work. The study aimed to investigate the efficacy of induction immunochemotherapy before radiotherapy (RT) for patients with locally advanced or metastatic esophageal cancer. Patients with unresectable locally advanced or metastatic esophageal cancer who received induction immunochemotherapy followed by RT (ICIs + RT group) and RT alone (RT group) were retrospectively identified in two cancer centers, respectively. Propensity score matching (PSM) was used to balance the potential confounders between the two groups. Overall survival (OS), progression-free survival (PFS), and recurrence patterns were evaluated. A total of 467 patients were reviewed, and 66 were matched in each group. After PSM, the 1- and 2-year OS rates were 84.6% and 57.9% in ICIs + RT group, and 71.1% and 43.0% in RT group (HR 0.60, 95% CI 0.36–1.00, p = 0.050). The absolute increase of restricted mean survival time (RMST) for OS in ICIs + RT group compared with RT group were 0.89 years (p = 0.023) at one year and 2.59 years at two years (p = 0.030). The median PFS time, 1- and 2-year PFS rates were 20.3 months, 69.3%, and 45.7% in ICIs + RT group, and 12.2 months, 51.4%, and 35.8% in RT group (HR 0.64, 95% CI 0.41–0.99, p = 0.045). The cumulative locoregional recurrence (LRR) rate was significantly lower in ICIs + RT group (1-year rate, 17.4% vs. 38.8%, p = 0.011), and distant metastasis (DM) rates were comparable (p = 0.755). Consolidation ICIs was associated with a trend of improved 1-year OS and PFS. Induction immunochemotherapy followed by RT might improve locoregional control and survival outcomes for patients with unresectable locally advanced or metastatic esophageal cancer. [ABSTRACT FROM AUTHOR]